Entering the second half of 2026, the pace of “screen brushing” on the AI pharmaceutical circuit continues to accelerate. Following the finalization of a cooperation of up to 600 million US dollars with Japan's Takeda Pharmaceuticals in early July, in just one month, Insilicon Smart and Borui Pharmaceuticals, a leading global CDMO, announced that they had reached a multi-target strategic cooperation. The potential total value of the two collaborations exceeded 3 billion US dollars. Due to the unknown cause of the disease and complicated biological mechanisms, IPF faced a ten-year impasse where no new drugs were introduced, and so far no domestically developed drugs have been approved for marketing. The targets and molecular structures of Rentosertib were all discovered by the full drive of the Insili Smart Pharma.ai platform, and has significant potential for global pioneering. This drug candidate, born in Zhangjiang, Shanghai, is a strong proof of innovation at the source of biomedicine in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.